Impact of FDA Black Box Advisory on Antipsychotic Medication Use
January 11, 2010 | Journal Article
The 2005 US Food and Drug Administration (FDA) "black box" advisory warning that atypical antipsychotic drugs increased risk of death with elderly patients with dementia led to fewer mentions of the drugs by physicians in the four years after implementation of the drug label requirement.